Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Primed To Re-Energize Respiratory Business, Rivals Close In

Executive Summary

Novartis’s once-daily triple combination inhaler, QVM149, and dual inhaler, QMF149, could be the first to gain approval for the treatment of uncontrolled asthma, as positive top-line Phase III data from the IRIDIUM and PALLADIUM trials are released. Other companies may not be far behind, however.

You may also be interested in...



Novartis Culls Fevipiprant After LackLUSTER Data

Any lingering hopes Novartis had that fevipiprant could become a blockbuster have disappeared and the Swiss major has ended development of the asthma drug after two more trials failed, this time for severe disease.

Orchard’s Gene Therapy Under Fast-Track Review At EMA

A handful of new products are under review at the European Medicines Agency. Orchard Therapeutics' gene therapy application will be fast-tracked; Roche's filing for its new flu treatment will not.

Blow To AZ As FDA Rejects COPD Contender

Issued with a complete response letter from the FDA, the company says it will now submit newer data showing the combination's effects on exacerbations.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel